Skip to content

Pasadena Star News

64°F
Friday, May 1st 2026

e-Edition

Trending:

Recent Quotes
My Watchlist
Indicators
Local Stocks
San Gabriel Valley
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Lexaria Bioscience Corp. - Common Stock (NQ:LEXX)

0.6919 +0.0419 (+6.45%)
Streaming Delayed Price Updated: 11:23 AM EDT, Jun 9, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Lexaria Bioscience Corp. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
26 27 Next >
News headline image
Lexaria's Animal Study Examining Next-Generation GLP-1 drugs is Underway
Via ACCESS Newswire
News headline image
Lexaria Attending the BIO International Convention, as Part of a Broader Business Development Program
Via ACCESS Newswire
News headline image
Lexaria Receives Independent Review Board Approval to Begin Human Pilot Study #7
Via ACCESS Newswire
News headline image
Lexaria Bioscience Releases Second Episode of Investor Video Series
Via ACCESS Newswire
News headline image
Lexaria Updates Progress on Human Study #7
Via ACCESS Newswire
News headline image
Lexaria Bioscience Launches Ongoing Investor Video Series to Expand Shareholder Communications
Via ACCESS Newswire
News headline image
Material Transfer Agreement Between Pharmaceutical Company and Lexaria is Extended
Via ACCESS Newswire
News headline image
Lexaria Launches New Study to Examine Next-Generation GLP-1 Drugs
Via ACCESS Newswire
News headline image
Lexaria Expects Oral GLP-1 Pills to Generate Billions in New Industry Sales
Via ACCESS Newswire
News headline image
Lexaria's New Animal Study Aims to Expand Valuable Intellectual Property
Via ACCESS Newswire
News headline image
Lexaria Applauds Eli Lilly's Foundayo(TM) Drug Approval
Via ACCESS Newswire
News headline image
Lexaria Applauds Eli Lilly's Foundayo(TM) Drug Approval
The number of oral weight-loss / diabetes drug treatments is expanding, increasing demand for the reduction of side effects 
Via TheNewswire.com
News headline image
Lexaria to Begin New Human Clinical Study in GLP-1
Via ACCESS Newswire
News headline image
Lexaria's Robust Patent Portfolio Continues to Grow
Via ACCESS Newswire
News headline image
Lexaria's Oral GLP-1 Drug Strategy Validated by Industry
Via ACCESS Newswire
News headline image
Lexaria Announces New R&D Plans for 2026
Via ACCESS Newswire
News headline image
Lexaria Announces Positive Final Results From Human Pilot Study #5
Via ACCESS Newswire
News headline image
Lexaria Awarded Six Additional Patents
Lexaria now has 60 patents granted around much of the world 
Via TheNewswire.com
Topics Intellectual Property
News headline image
Lexaria Awarded Six Additional Patents
Via ACCESS Newswire
News headline image
Lexaria Releases Annual Letter from the CEO
Via ACCESS Newswire
News headline image
Lexaria Releases Additional Results from its Successful Phase 1b Study GLP-1-H24-4
Via ACCESS Newswire
News headline image
THE FOCUS DOCTRINE: 5 Assets Securing the 2026 Biological Choke Point
ISSUED ON BEHALF OF DOSEOLOGY SCIENCES INC. 
From USA News Group
Via GlobeNewswire
News headline image
Primary Endpoint Successfully Achieved in Lexaria's Phase 1b Study GLP-1-H24-4
Via ACCESS Newswire
News headline image
Lexaria Bioscience Corp. Announces Closing of $3.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
Via ACCESS Newswire
News headline image
Lexaria Bioscience Corp. Announces $3.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
Via ACCESS Newswire
News headline image
Material Transfer Agreement Between Pharmaceutical Company and Lexaria is Extended
Via ACCESS Newswire
News headline image
Lexaria Bioscience Corp. Provides Strategic Update
Via ACCESS Newswire
News headline image
Lexaria Bioscience Corp. Announces Closing of $4.0 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
Via ACCESS Newswire
News headline image
Lexaria Bioscience Corp. Announces $4.0 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
Via ACCESS Newswire
News headline image
Lexaria's Technology Supports Higher Levels of the GLP-1 Drug Semaglutide in Brain
Via ACCESS Newswire
< Previous 1 2 3 4 5 6 7 8 9
...
26 27 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.